FDA Among Regulatory Authorities Reeling From Brexit Bombshell

 
• By Derrick Gingery and Ryan Nelson

Commissioner Robert Califf says FDA has no firm plan but will “react to whatever happens” following the UK’s momentous decision to leave the EU. The European Medicines Agency also is taking a wait-and-see approach, while regulated industries brace for potential compliance, R&D and IP challenges in Brexit’s aftermath.

Nearly half of voting Brits and many millions more around the world continue to process their shock at the UK’s decision to withdraw from the European Union, with more questions than answers at present as to the momentous event’s ramifications.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

More from Policy & Regulation